In its role as a “Terawatt Partner,” Aramco Americas will gain access to activities within Greentown’s industry and entrepreneurial network. Photo via greentownlabs.com

Houston-based Aramco Americas, an arm of the Saudi Arabian energy giant, has joined climatetech incubator Greentown Labs as a top-tier partner.

“Aramco is committed to advancing technology solutions to lower carbon emissions. This partnership with Greentown Labs will deepen our ongoing engagement with climatetech innovators and startups,” Nabeel AlAfaleg, president and CEO of Aramco Americas, says in a news release.

In its role as a “Terawatt Partner,” Aramco Americas will gain access to activities within Greentown’s industry and entrepreneurial network. In addition, Aramco Americas will participate in Greentown’s Industry Leadership Council, an advisory group. Jim Sledzik, managing director of Aramco Ventures North America, will serve on the council.

Aramco’s partnership with Greentown Labs comes on the heels of last year’s announcement of the company’s $1.5 billion fund to invest in technology that supports the ongoing energy transition. Managed by Aramco Ventures, the VC arm of Aramco, the fund focuses on carbon capture and storage, greenhouse gas emissions, energy efficiency, nature-based climate solutions, digital sustainability, hydrogen, ammonia, and synthetic fuels.

To date, Aramco Ventures has invested in 22 startups and high-growth companies involved in the sustainability sector.

“Aramco Americas and Aramco Ventures have already exemplified what we look for in a partner: support of our entrepreneurs through investment and pilot opportunities, and engaging with our communities in Houston and Boston in the spirit of sustainability and climate action,” says Kevin Taylor, interim CEO and chief financial officer of Greentown Labs.

Greentown operates climatetech incubators in Houston and Somerville, Massachusetts.

Jim Sledzik, North American managing director of Saudi Aramco Energy Ventures, will serve on Greentown’s Industry Leadership Council. Photo via Aramco

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”